行情

TROV

TROV

Trovagene
NASDAQ

实时行情|Nasdaq Last Sale

0.8800
-0.1300
-12.87%
盘后: 0.8800 0 0.00% 17:24 04/01 EDT
开盘
1.000
昨收
1.010
最高
1.035
最低
0.8200
成交量
21.54万
成交额
--
52周最高
5.83
52周最低
0.7010
市值
898.51万
市盈率(TTM)
-0.3227
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测TROV价格均价为14.50,最高价位23.00,最低价为6.00。

EPS

TROV 新闻

更多
  • Trovagene Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer (mCRC) Trial Abstract for Presentation at the 2020 ASCO Annual Meeting
  • PR Newswire · 15小时前
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • Trovagene Announces Three New Nominees for Election to Board of Directors
  • PR Newswire · 03/05 13:15
  • TrovaGene EPS beats by $0.14
  • seekingalpha · 02/28 02:39

所属板块

生物技术和医学研究
-4.52%
制药与医学研究
-2.91%

热门股票

代码
价格
涨跌幅

TROV 简况

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway.
展开

微牛提供TrovaGene Inc(NASDAQ-TROV)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的TROV股票新闻,以帮助您做出投资决策。